{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-004181","form_type":"8-K","ticker":"VNOV","cik":"0001699709","company_name":"VitaNova Life Sciences Corp","filed_at":"2023-06-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.099655+00:00","generated_at":"2026-06-14T00:21:07.784039+00:00","sec_items":["5.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xianchang Ma acquires 86.3% of Yijia Group; appointed CEO, President, CFO and Director","bullets":["Barry Sytner sold 5,066,250 shares (86.3% of outstanding) to Xianchang Ma for $470,562 on June 14, 2023.","Sytner resigned as CEO, President, CFO, and Director; Ma appointed to all those roles effective June 14, 2023.","Xianchang Ma, age 48, is CEO and director of Tengjun Biotechnology Corp; founded Jinan Tengiun Biological Technology in 2014.","Purchase price paid from Ma's personal funds; agreement included escrow and conditions such as filing of Form 10-K."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-004181","json":"https://secwatch.observer/filing/0001683168-23-004181.json","markdown":"https://secwatch.observer/filing/0001683168-23-004181.md","text":"https://secwatch.observer/filing/0001683168-23-004181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/yijia_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:21:07.784039+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2969d2487d","claim":"Xianchang Ma was appointed as President at VitaNova Life Sciences Corp.","evidence_excerpt":"On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"32dff5eb90","claim":"Barry Sytner resigned as Chief Executive Officer at VitaNova Life Sciences Corp.","evidence_excerpt":"On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"499e844ffb","claim":"Barry Sytner resigned as President at VitaNova Life Sciences Corp.","evidence_excerpt":"On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"cf28c068fb","claim":"Barry Sytner resigned as Chief Financial Officer at VitaNova Life Sciences Corp.","evidence_excerpt":"On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"d09b623576","claim":"Xianchang Ma was appointed as Director at VitaNova Life Sciences Corp.","evidence_excerpt":"On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"df5970949e","claim":"Xianchang Ma was appointed as Chief Financial Officer at VitaNova Life Sciences Corp.","evidence_excerpt":"On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"eb0e391b13","claim":"Barry Sytner resigned as Director at VitaNova Life Sciences Corp.","evidence_excerpt":"On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f3b80e95e5","claim":"Xianchang Ma was appointed as Chief Executive Officer at VitaNova Life Sciences Corp.","evidence_excerpt":"On June 14, 2023, the sole Director of the Company, Mr Sytner, resolved to step down from his positions as Chief Executive Officer, President, Chief Financial Officer and Director of the Company, and for Mr. Xianchang Ma to be appointed as the Chief Executive Officer, President, Chief Financial Officer and Director of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"951bb68182817cee5f1639a5088efdfb623870e4","claim":"VitaNova Life Sciences Corp underwent a change of control involving Xianchang Ma for $470,562 (closed 2023-06-14).","evidence_excerpt":"of common stock of the Company to Mr. Ma, constituting approximately 86.3% of the issued and outstanding shares of the Company as of May 2, 2023, for a total consideration of $470,562, derived from the purchaser’s personal funds. The Securities Purchase Agreement was closed on June 14, 2023. Following the closing, Mr. Ma acquired a beneficial interest in","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699709/000168316823004181/0001683168-23-004181-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Xianchang Ma"},{"label":"Consideration","value":"$470,562"},{"label":"Closing","value":"2023-06-14"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}